Drug Trial Radar · NCT05396885
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma (iMMagine-1)
Last checked: Nov 20, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
136
Actual
Start
Jul 15, 2022
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Kite, A Gilead CompanyGilead Sciences (GILD)
- Sponsor type
- Industry
- Collaborators
- Arcellx, Inc.
- First posted
- May 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase II study of anitocabtagene-autoleucel (formerly CART-ddBCMA) for patients with relapsed or refractory multiple myeloma. Anitocabtagene-autoleucel is a BCMA-directed CAR-T cell therapy.
Conditions
- Multiple Myeloma
Interventions
anitocabtagene-autoleucelBiological
Anitocabtagene-autoleucel-directed CAR T-cell therapy using a novel, synthetic binding domain, called a D-domain
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: 24 Months
Locations
18 sites in 1 country. Site status is shown where the registry gives one.
HonorHealth Cancer Transplant Institute
Scottsdale, Arizona
University of Arkansas for Medical Sciences
Little Rock, Arkansas
Colorado Blood Cancer Institute
Denver, Colorado
Moffitt Cancer Center
Tampa, Florida
Northside Hospital
Atlanta, Georgia
University of Chicago Medical Center
Chicago, Illinois
University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana-Farber Cancer Institute
Boston, Massachusetts
Karmanos Cancer Institute
Detroit, Michigan
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey
Levine Cancer Institute
Charlotte, North Carolina
Oregon Health & Science University (OHSU)
Portland, Oregon
University of Texas Southwestern Medical Center
Dallas, Texas
The University of Texas MD Anderson Cancer Center
Houston, Texas
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah
University of Wisconsin Clinical Science Center
Madison, Wisconsin
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.